CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in
precision genetic medicine for rare diseases, today announced that it is offering to sell, subject to market and other conditions,
$500,000,000 in shares of its common stock in an underwritten public offering. Sarepta also intends to grant the underwriters a
30-day option to purchase an additional $75,000,000 in shares of its common stock offered in the public offering.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Credit Suisse are acting as joint book-running
managers of the proposed offering.
Sarepta intends to use the net proceeds from the offering principally for the continuation and initiation of
further clinical trials, commercialization, manufacturing, business development activities including the potential licensing or
acquisition of complementary products and technologies and other general corporate purposes. The offering is subject to market and
other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or
terms of the offering.
The shares are being offered by Sarepta pursuant to an effective shelf registration statement that was
previously filed with the Securities and Exchange Commission (SEC). The offering is being made only by means of a written
prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating
to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.
When available, copies of the preliminary prospectus supplement relating to these securities may also be obtained from the offices
of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866)
471-2526, or by email at prospectus-ny@ny.email.gs.com; or J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com.
The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of
Sarepta, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements and Information
This press release contains statements that are forward-looking within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including the statements about the completion,
timing and size of the proposed public offering of Sarepta’s common stock and the intended use of net proceeds. These
forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control, including risk and
uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public
offering. There can be no assurance that Sarepta will be able to complete the public offering on the anticipated terms, or at all.
Applicable risks also include those that are included in the “Risk Factors” section of Sarepta’s Annual Report on Form 10-K for the
year ended December 31, 2017, and any subsequent SEC filings, including the prospectus supplement related to the proposed offering
to be filed with the SEC. Any forward-looking statement in this press release represents Sarepta’s views only as of the date of
this press release and should not be relied upon as representing its views as of any subsequent date. Sarepta does not undertake
any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as
required by applicable law.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O Group
Jerica Pitts, 312-858-3469
jpitts@w2ogroup.com
